CT:IQ welcomes Roche to Steering Committee

We are delighted to welcome a new member to CT:IQ’s Steering Committee, Roche. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. […]

AccessCR joins CT:IQ Steering Committee

We are pleased to announce AccessCR has joined CT:IQ’s Steering Committee. AccessCR is a social enterprise providing services to the research sector to engage with and involve health consumers in research and development with a view to helping improve the relevance, efficiency of, and participant experience in, clinical trials that lead to advancements in health […]

Get the D.I.R.T. on Digitalisation of Clinical Trials Summit & Dinner

On 23 November, CT:IQ will be partnering with ARCS Australia on the Summit Get the D.I.R.T. on digitalisation of clinical trials. The Summit will provide a forum for discussing the potential benefits and challenges of digitalisation, and to agree on priorities to ensure Australia leverages digital technologies to progress effective and inclusive medical research. Who should attend? […]

Consentic joins CT:IQ Steering Committee

We are delighted to announce that Consentic has joined CT:IQ’s Steering Committee. Consentic is an eConsent platform for medical, dental and clinical trial consent, providing a comprehensive library of patient-tested, medicolegally-reviewed consent animations with interactive checklists and secure electronic consent forms. Consentic optimises and streamlines consent, and is clinically proven to result in enhanced patient understanding, […]

Welcome Pharmaceutical Product Development (PPD) to CT:IQ Steering Committee

CT:IQ is delighted to welcome Pharmaceutical Product Development (PPD) to the Steering Committe. PPD, part of Thermo Fisher Scientific, is a leading global contract research organisation (CRO) focused on delivering life-changing therapies. PPD provides comprehensive lab services, integrated drug development, clinical trial therapeutic expertise and lifecycle management services. In December 2021, PPD became a wholly owned […]

CT:IQ welcomes The Institute of Haematology at the Royal Prince Alfred Hospital

The RPAH Institute of Haematology Research Unit is a leader in both clinical medicine and laboratory research spanning malignant and non-malignant haematology. The clinical trials unit has been very active in multiple diseases over many years, investigating and making available many state-of-the-art agents and protocols for their patients. The Institute of Haematology is one of […]

Monash Health joins CT:IQ Steering Committee

We are delighted to welcome a new member to CT:IQ’s Steering Committee, Monash Health. Monash Health is Victoria’s largest public health service providing safe, high-quality care to one-quarter of Melbourne’s population, across the entire lifespan, from pre-birth to end-of-life. Research Support Services (RSS) is the central human research administration office for all human research projects […]

IQVIA joins CT:IQ Steering Committee

We are delighted to announce that IQVIA has joined CT:IQ’s Steering Committee. IQVIA is the largest healthcare data science company and world leader in human data science technology, using data, technology, advanced analytics, and expertise to help customers drive healthcare forward. Together with the companies they serve, IQVIA is enabling a more modern and effective […]

BDHP announces new name

On 16 November 2021, Brisbane Diamantina Health Partners announced that it will be known as Health Translation Queensland. The name change is the result of significant engagement with their stakeholders, and efforts to better understand their role as a key research translation centre in Queensland. The new name reflects the scope and intent of the […]

CT:IQ Welcomes emyria to Steering Committee

emyria is focused on data-backed drug development. emyria’s treatments and drug development programs address unmet needs and are unique in that they are informed by Real World Evidence (RWE) they create with patients across their clinical service. Patients are part of the clinical research journey. CT:IQ is thrilled to welcome emyria to the Steering Committee.